Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Dasatinib + Gemcitabine in Resected Pancreatic Cancer
NCT01234935Phase 2Completed
- Sponsor
- TRIO
- Start
- Jan 2011
- Primary completion
- Nov 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in pancreatic adenocarcinoma (PDAC), sponsored by TRIO. Started Jan 2011; status: completed.
02
Drugs
dasatinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01234935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01234935.